SUPRIYA Supriya Lifescience Q4 FY25 results (Jan–Mar 2025) and concall
Supriya Lifescience delivered its strongest year yet in FY25, achieving record revenue of Rs. 696 crores, a 22% YoY increase, and EBITDA of Rs. 261 crores, up 51% YoY, with margins at 37%. The company reaffirmed its FY26 guidance of ~20% revenue growth and 33-35% EBITDA margins, while targeting Rs. 1,000 crores in revenue by FY27. Growth was driven by capacity enhancement, new market penetration, and backward integration, with exports accounting for 85% of revenue.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 166 | 186 | 184 |
| EBITDA | 65 | 66 | 68 |
| Net profit | 46 | 47 | 50 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
